How did Cencora's revenue and expenses trend in Q1 2025?

**Cencora's Revenue and Expenses Trend in Q1 2025**:

1. **Revenue Growth**: Cencora experienced a robust increase in revenue, with a reported growth of 13% year-over-year, reaching $81.5 billion in Q1 2025. This growth was primarily driven by strong performance in the U.S. Healthcare Solutions segment and the acquisition of Retina Consultants of America, which reinforced leadership in specialty services.
2. **Segmental Analysis**: Within the Alliance Healthcare segment, there was a significant increase in revenue, with a reported $23.06 billion. The Animal Health segment also contributed positively, with revenue amounting to $5.37 billion. The Human Health segment remained the largest, reporting $259.97 billion in revenue. The International Healthcare Solutions segment showed a notable $28.63 billion in revenue, reflecting Cencora's expanding global footprint.

3. **Net Interest Income and Total Expenses**: Unfortunately, data on net interest income and total expenses for Q1 2025 is not available. However, CFO James Cleary noted a 12.5% rise in operating expenses, primarily due to litigation and distribution costs, which impacted the net income. The decline in gross profit margin by 20 basis points to 3.11% was attributed to higher sales of low-margin GLP-1 products and lower sales of COVID-19 vaccines and therapies.
4. **Earnings Performance**: Cencora reported an adjusted diluted EPS of $3.73, which represented a 13.7% increase from the prior year. Despite the revenue growth, the GAAP diluted EPS of $2.50 fell short of the estimated EPS of $2.92, missing the earnings expectation. However, the company raised its full-year EPS guidance to a range of $15.25 to $15.55, reflecting confidence in continued strong performance.

In conclusion, Cencora's Q1 2025 financial performance was marked by substantial revenue growth, driven by strategic segmental performance and acquisitions, despite challenges posed by increased expenses and margin pressures.